Handelsavisen
prelaunch
Companies Healthcare 6527.TWO
65
6527.TWO TPEx Medical Equipment, Supplies & Distribution

6527.Two

$71,00
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,8B TWD
P/E
EV / Rev
Div yield
3,36 %
Op margin
19,1 %
ROE
14,3 %
Net margin
15,5 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

Business. 6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
14,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6527.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6527.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6527.TWO operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company maintains a strong liquidity position, with a current ratio of 2.45 and cash and equivalents amounting to TWD 132,018,000. Its debt-to-equity ratio is 0.01, indicating a conservative capital structure with minimal reliance on long-term debt. The price-to-book ratio of 1.74 suggests that the company is trading at a premium to its book value, which may reflect market confidence in its asset base and earnings potential.

    Profitability metrics show that the company is performing well relative to industry norms. It reports a return on equity (ROE) of 14.29% and a return on assets (ROA) of 11.35%, both of which are strong indicators of efficient capital utilization and asset management. The net income of TWD 146,980,000 and operating income of TWD 180,945,000 further support the company's profitability. Gross profit of TWD 331,879,000 indicates a healthy margin, although the exact comparison to industry medians is not provided in the data.

    The company's revenue is concentrated in the medical equipment, supplies, and distribution segment, as disclosed in its financials. There is no indication of geographic diversification in the provided data, suggesting that the company's operations are likely centered in a specific region. This concentration may expose the company to regional economic or regulatory risks.

    Looking ahead, the company is expected to maintain a stable growth trajectory. While specific numeric deltas for the current and next fiscal years are not provided, the company's strong operating cash flow of TWD 139,131,000 and revenue of TWD 949,049,000 suggest a solid foundation for future growth. The company's capital expenditure of TWD -185,187,000 indicates ongoing investment in infrastructure and operations, which could support long-term expansion.

    The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves further support this assessment. There is no evidence of dilution potential in the basic shares outstanding, as the number of basic and diluted shares is the same. The company has not made any adjustments to its valuations that would suggest a need for dilution or restructuring.

    Recent events, including filings and transcripts, do not indicate any material changes or risks to the company's operations. The absence of filing-based liquidity or dilution flags suggests that the company is currently in a stable financial position. However, ongoing monitoring of capital expenditures and operating cash flow will be important to assess the sustainability of its growth and profitability.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 2.45 and minimal long-term debt.
    • It demonstrates high profitability with a return on equity of 14.29% and a return on assets of 11.35%.
    • The company's revenue is concentrated in the medical equipment, supplies, and distribution segment, with no geographic diversification disclosed.
    • The company is expected to maintain a stable growth trajectory, supported by strong operating cash flow and revenue.
    • Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $71,00
    Market cap
    $1.79B
    Enterprise value
    $1.67B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    12.0x
    P / B
    1.7x
    P / Tangible book
    1.7x
    Tangible book
    $1.03B
    Net cash
    $120.3M
    Current ratio
    2.5
    Debt / equity
    0.0
    ROA
    11.3%
    ROE
    14.3%
    Cash conversion
    95.0%
    CapEx / revenue
    -19.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin19,1 %Above P75
    Net Margin15,5 %Above P75
    ROE14,3 %Above P75
    Capex / Rev-19,5 %Bottom quartile
    D/E0,01Above P75
    Cash Conv0,95Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 6527.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • William WangChairman of the Board, Chief Executive Officer

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6527.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage